Introduction
============

Transforming growth factor-β (TGF-β) is a member of the TGF-β super-family, which also includes bone morphogenic proteins, activins, inhibins, and other related factors (Moustakas and Heldin, [@B70]). Mammals have three different forms of TGF-β (β1, β2, and β3). The ligands initiate their cellular effects using high-affinity cell surface receptors (TGF-β type I and type II receptors). The importance of each TGF-β isoforms in mammalian biology is highlighted by their lethal phenotypes in TGF-β-null mice. For instance, 50 percent of TGF-β1-null mouse fetuses die around 10.5 days *post coitum* (dpc) due to abnormal development of the yolk sac, characterized by defective vasculogenesis and/or anemia during embryonic development (Dickson et al., [@B24]). Even in newborn TGF-β1-null mice, severe multi-organ autoimmunity and multi-focal inflammation develop after birth: the mice die within 3 weeks due to widespread inflammatory disease (Shull et al., [@B99]; Kulkarni et al., [@B53]). TGF-β2-null mice die in the perinatal period due to cyanotic heart disease and pulmonary insufficiency (Sanford et al., [@B90]). TGF-β3-null mice die of craniofacial defects, most notably cleft palate (Proetzel et al., [@B84]). Thus, TGF-β signaling is an important for tissue growth and morphogenesis with clear roles in processes such as vasculogenesis, angiogenesis, immune response, and development of the palate during embryonic development, and homeostasis after birth. Although TGF-β was initially identified as a growth factor that induced the growth of rodent fibroblasts in semi-solid agar, TGF-βs are now also known to be potent growth inhibitors for many different cell types, including epithelial cells, endothelial cells, hematopoietic progenitor cells, and lymphocytes (Siegel and Massague, [@B101]). Albumin promoter-mediated overexpression of TGF-β1 in transgenic mice can result in abnormal phenotypes characterized by hepatocyte apoptosis and liver fibrosis, and also causes glomerulonephritis, renal failure, arteritis, myocarditis, and atrophic changes in pancreas and testis (Sanderson et al., [@B89]). Thus, TGF-βs play a pivotal role in a diverse range of cellular responses, including cell proliferation, apoptosis, differentiation, migration, adhesion, angiogenesis, and synthesis of extracellular matrix (ECM) components (Feng and Derynck, [@B29]; ten Dijke and Arthur, [@B108]; Wakefield and Stuelten, [@B118]), and thereby control embryonic development and adult tissue homeostasis. Hence, any dysregulation in the control of TGF-β signaling contributes to the development of severe consequences like as fibrosis, autoimmune and vascular diseases, and cancer (Sellheyer et al., [@B97]; Galbreath et al., [@B31]; Sanderson et al., [@B89]; Zhou et al., [@B128]; Blobe et al., [@B11]; Feng and Derynck, [@B29]; ten Dijke and Arthur, [@B108]; van Bezooijen et al., [@B114]; Wakefield and Stuelten, [@B118]). Because TGF-β and its receptors widely express in all cell types, a tight regulation at every step of its synthesis, activation, and the downstream signaling must be required for keeping tissue homeostasis in normal liver. Latency is one mechanism by which to control the activity of a cytokine; latency prevents the cytokine from eliciting a response until conversion to the active form and may also allow the cytokine to circulate and reach its target cell. TGF-β is synthesized and secreted as a latent complex and is converted from the latent form into the active one to bind to its high-affinity TGF-β receptor. Recently, activation of latent TGF-β is being increasingly recognized as a critical step in the control of TGF-β activity (Koli et al., [@B50]; Annes et al., [@B3]; Hyytiainen et al., [@B45]; Wipff and Hinz, [@B121]). Indeed, enhanced expression of TGF-β mRNA and protein levels does not often correlate with active TGF-β level (Theodorescu et al., [@B110]). In addition, latent TGF-β activation can be induced independently of transcription (Boulanger et al., [@B13]). The aim of this review is to summarize the present knowledge of TGF-β activation mechanism in the liver.

Synthesis (Please See Figure [1](#F1){ref-type="fig"})
======================================================

Small latent complex
--------------------

The isoforms of TGF-β1, -2, and -3 are encoded as large precursor proteins of 390--412 amino acids in size, and each isoform is the product of a separate gene (Derynck et al., [@B23]; Gentry and Nash, [@B33]; ten Dijke et al., [@B109]; Schlunegger and Grutter, [@B93]). TGF-β proteins undergo several processing steps intracellularly prior to their secretion. The most important step is the proteolytic digestion of precursors by the endopeptidase furin, which cleaves the TGF-β protein between amino acids 278 and 279 (Dubois et al., [@B26]; Blanchette et al., [@B10]). The proteolysis yields two products that assemble into dimers. One is latency-associated peptide (LAP), a 65- to 75-kDa dimer from the N-terminal region. The other is mature TGF-β, a 25-kDa dimer from the C-terminal portion (Gentry and Nash, [@B33]; Blanchette et al., [@B10]; Munger et al., [@B72]). A common feature of TGF-β is that its N-terminal portion (LAP) remains non-covalently associated with the rest of the portion (termed small latent complex), despite the cleavage of the precursor (Derynck et al., [@B23]; Gentry and Nash, [@B33]; ten Dijke et al., [@B109]; Schlunegger and Grutter, [@B93]; Dubois et al., [@B26]; Blanchette et al., [@B10]; Munger et al., [@B72]). The presence of LAP facilitates transit of TGF-β from the cell (Lopez et al., [@B56]). Interestingly, cells transfected with mature sequences of TGF-β1 fail to secrete proteins into medium, whereas cells transfected with LAP and mature sequences of TGF-β1 can do this (Gray and Mason, [@B35]). Thus, LAP is required for the correct folding of the TGF-β homodimer and its secretion from cells. Furthermore, LAP shields the receptor binding epitope of mature TGF-β, indicating that LAP makes TGF-β biologically inactive and prevents interactions of TGF-β with receptors.

![**Illustration of the sequential steps in the synthesis of TGF-β latent complex and secretion**. (1) TGF-β is synthesized as a precursor protein; (2) Two TGF-β precursor proteins dimerize through disulfide bridges; (3) TGF-β-dimer precursor is cleaved by furin to yield the small latent TGF-β complex, in which latency-associated peptide (LAP; light blue) and mature TGF-β peptide (dark blue) are connected by non-covalent bonds; and (4) the large latent complex is formed by covalent linking between small latent complex and latent TGF-β binding protein (LTBP), then secreted and incorporated into extracellular matrix.](fphys-03-00012-g001){#F1}

Large latent complex
--------------------

Small latent complex is associated with a large protein termed latent TGF-β binding protein (LTBP) via disulfide bonds. Mammalian cells express four different LTBP isoforms, of which three (LTBP-1, -3, and -4) can associate with LAP. The trimolecular complex of TGF-β, LAP, and LTBP is referred to as the large latent complex. In most cell types, TGF-β is secreted as large latent TGF-β complexes (Olofsson et al., [@B80]; Taipale et al., [@B106]), although some cells (such as those of the bone cell line UMR-106) secrete small latent complex (Dallas et al., [@B21]). LTBPs contain multiple epidermal growth factor-like repeats and four cysteine-rich domains that are also found in fibrillins. During secretory processes, the cysteine 33 residue of TGF-β1--LAP becomes disulfide-linked to the third cysteine-rich domain in LTBP-1 (Saharinen et al., [@B88]). In mice with the mutation (cysteine 33 residue to serine) of TGF-β1--LAP, mutated TGF-β1--LAP cannot covalently complex with any LTBP, and TGF-β1 is secreted as small latent complex (Yoshinaga et al., [@B124]). Furthermore, mice with the mutation of cysteine 33 in LAP display decreased levels of active TGF-β1 compared with control mice, show a milder multi-organ inflammation, and have a longer life span than TGF-β1-null mice (Yoshinaga et al., [@B124]). Large latent TGF-β1 complex (small latent TGF-β1 with LTBP) and the free form of LTBP are secreted rapidly from cells (Miyazono et al., [@B65]). In contrast, the small latent form of TGF-β without LTBP is secreted very slowly (Miyazono et al., [@B65]), and the majority of latent TGF-β without LTBP is retained in the *cis* aspect of the Golgi apparatus (Miyazono et al., [@B66]). Thus, LTBP associates with small latent TGF-β rapidly inside the cells, and this association is important for the proper assembly and secretion of latent TGF-β complexes (Miyazono et al., [@B65]).

ECM anchoring
-------------

After secretion, LTBP also plays a critical role in targeting small latent TGF-β for deposition in the ECM (Taipale et al., [@B106]; Nunes et al., [@B77]). LTBP belongs to the fibrillin family of ECM proteins, and LTBP shares homology with fibrillins, which are major constituents of connective tissue microfibrillar structure (Kanzaki et al., [@B48]; Munger et al., [@B72]). The C-terminal region of LTBP-1 binds to the N-terminal region of fibrillin-1 (Isogai et al., [@B47]). In addition, LTBP-1 is covalently cross-linked to ECM proteins such as fibronectin (Dallas et al., [@B22]) via its N-terminal region (Taipale et al., [@B106]; Nunes et al., [@B77]). Indeed, LTBP-1 colocalizes with both fibrillin-1 and fibronectin *in vitro* by immunostaining (Taipale et al., [@B107]; Dallas et al., [@B22]; Massam-Wu et al., [@B62]), suggesting that fibrillin-1and fibronectin can associate with LTBP-1. The treatment of fetal rat calvarial osteoblasts with a 70-kDa N-terminal fibronectin fragment, which inhibits fibronectin assembly, impairs incorporation of LTBP-1 into the ECM in culture (Dallas et al., [@B22]). In addition, although fibronectin-null embryonic fibroblasts secrete a large amount of LTBP-1 into medium, they fail to incorporate LTBP-1 into the ECM (Dallas et al., [@B22]). This covalent association between LTBP-1 and the ECM depends on transglutaminase-mediated cross-linking, because little LTBP-1 is recovered from matrix digests that have been treated with transglutaminase inhibitors (Nunes et al., [@B77]). Thus, the N-terminal and C-terminal binding sites of LTBP-1 are central for anchoring latent TGF-β to fibrillin-1 and fibronectin (Hyytiainen et al., [@B46]; Unsold et al., [@B113]), and this anchoring influences the release of TGF-β from LAP, a process called latent TGF-β activation (Annes et al., [@B2]). A number of genetic studies suggest that the absence of or a mutation in LTBP-binding ECMs such as fibrillin-1 and fibronectin results in increased TGF-β activity and Smad signaling, whereas the absence of or mutation in latent TGF-β activators and LTBPs results in decreased activity (Neptune et al., [@B76]; Koli et al., [@B51]; Mazzieri et al., [@B64]; Yoshinaga et al., [@B124]; Loeys et al., [@B55]; Table [1](#T1){ref-type="table"}). Efficient latent TGF-β activation requires appropriate localization of latent complexes in the ECM (Annes et al., [@B3]). Following the N-terminal domain of LTBP, there is a protease-sensitive region, called the hinge region. Large latent TGF-β is released from the ECM by proteolytic cleavage at this region (Taipale et al., [@B106]). Thus, the small latent complex, which consists of precursors of mature TGF-β and LAP, covalently interacts with LTBP and is secreted thereafter as a large latent complex. The large latent complex is then associated with the ECM such as fibrillin and fibronectin (Figure [2](#F2){ref-type="fig"}). Extracellular TGF-β activity is regulated at the level of bioavailability (release of latent TGF-β from ECM) and latency (release of active TGF-β from the latent complex). Such a well and tightly orchestrated regulation in latency of TGF-β enables the immediate and highly localized response to type-specific tissue injury without *de novo* synthesis. In this scenario, the ECM is potentially an important regulator of latent TGF-β complexes. One of the compelling themes in recent years is to clarify the crucial roles of integrin β6, thrombospondin-1 (TSP-1), LTBPs, fibrillin-1, and fibronectin in regulating local TGF-β activity and locally anchored TGF-β availability in pathological process (Hynes, [@B44]).

###### 

**Altered TGF-β activity in knockout or mutant mice**.

  Gene target           Treatment                              TGF-β activity   Reference
  --------------------- -------------------------------------- ---------------- -------------------------------
  Integrin β6           Bleomycin-induced lung fibrosis        Decrease         Munger et al. ([@B73])
                        BDL-induced liver fibrosis             Decrease         Wang et al. ([@B119])
  TSP-1                                                        Decrease         Crawford et al. ([@B19])
                        PH-induced liver regeneration          Decrease         Hayashi et al. ([@B39])
                        Bleomycin-induced lung fibrosis        Not affected     Ezzie et al. ([@B28])
                        Thrombopoietin-induced myelofibrosis   Not affected     Evrard et al. ([@B27])
  Fibronectin           CCl~4~-induced liver injury            Increase         Moriya et al. ([@B67])
  LTBP1                                                        Decrease         Todorovic et al. ([@B111])
  LTBP3                                                        Decrease         Dabovic et al. ([@B20])
  LTBP4                                                        Decreases        Sterner-Kock et al. ([@B104])
  BMP-1 and Tll1                                               Decrease         Ge and Greenspan ([@B32])
  Fibrillin-1                                                  Increase         Neptune et al. ([@B76])
  MAGP-1                                                       Decrease         Weinbaum et al. ([@B120])
  Fibulin-4                                                    Increase         Hanada et al. ([@B38])
  Emilin-1                                                     Increase         Zacchigna et al. ([@B127])
  TGF-β1--LAP (C33 S)                                          Decrease         Yoshinaga et al. ([@B124])

*TGF-β, transforming growth factor-β; BDL, bile duct ligation; TSP-1, thrombospondin-1; PH, partial hepatectomy; LTBP, large latent TGF-β-binding protein; BMP-1, bone morphogenetic protein-1; TII1, tolloid-like 1; CCl~4~, Carbon tetrachloride; MAGP-1, microfibril-associated glycoprotein-1; LAP, latency-associated peptide; C33S, 33 cysteine mutated to serine*.

![**Proposed model of TGF-β latent complex and active TGF-β signaling**. The LTBP is covalently cross-linked to ECMs such as fibronectin and fibrillin via its N-terminal and C-terminal region, respectively. The small latent TGF-β complex is bound covalently to the third cysteine-rich domain of LTBP. In response to tissue injury, release of active TGF-β from latent complex and/or conformational change such as exposure of the TGF-β receptor binding site is induced. Binding of active TGF-β with the TGF-β receptor type II leads to the phosphorylation and recruitment of TGF-β receptor type I into a heteromeric receptor complexes. The serine/threonine kinase activity of the activated complex phosphorylates Smad2 and Smad3 that both bind to Smad4 and translocate into the nucleus to enhance gene transcription by cooperating with DNA transcription factors.](fphys-03-00012-g002){#F2}

Mechanisms of TGF-β Activation
==============================

Local activation of latent (inactive) TGF-β complexes is a critical event in regulating TGF-β function *in vivo*. In response to tissue damage, TGF-β is released from LAP or latent TGF-β complex undergoes conformational changes, and therefore, active TGF-β is exposed to the TGF-β receptor binding site (Annes et al., [@B3]). Binding of active TGF-β to the TGF-β receptor type II leads to the phosphorylation and recruitment of TGF-β receptor type I into a heteromeric receptor complex. The serine/threonine kinase activity of the activated complex phosphorylates Smad2 and Smad3 that both bind to Smad4 and translocate into the nucleus to enhance gene transcription by cooperating with DNA transcription factors (Feng and Derynck, [@B29]; Massague et al., [@B61]; Matsuzaki, [@B63]; Figure [2](#F2){ref-type="fig"}). The activation mechanism to generate active TGF-β from latent complexes has been extensively studied, and several modulators of TGF-β activity *in vivo* have been proposed.

Integrin-mediated TGF-β activation
----------------------------------

Recent studies show that integrins-related genetic models can down-regulate TGF-β activation *in vivo* (Munger et al., [@B73]; Yang et al., [@B123]). Integrins are heterodimeric cell adhesion molecules and transmembrane receptors that link the ECM to the cytoskeleton, and have an important role in cell adhesion, cell proliferation, differentiation, and cell migration (Hynes, [@B42], [@B43]; van der Flier and Sonnenberg, [@B115]). Integrins are composed of α- and β-subunits (18 α- and 8 β-subunits), both of which are glycoproteins consisting of large extracellular domains and, in most cases, a short cytoplasmic domain (van der Flier and Sonnenberg, [@B115]). Both TGF-β1 and LAP have an RGD sequence, a binding motif in ligands for α~v~ integrins. Among the α~v~ integrins, the integrins α~v~β~1~, α~v~β~3~, α~v~β~5~, α~v~β~6~, α~v~β~8~, α~5~β~1~, α~8~β~1~, and α~IIb~β3 are RGD binding integrins. Mice with the integrin-binding RGD motif mutated to RGD recapitulate all major phenotypes of TGF-β1-null mice, including multi-organ inflammation and defects in vasculogenesis (Yang et al., [@B123]). Two of these integrins (α~v~β~6~ and α~v~β~8~) bind and efficiently activate latent TGF-β1 and -β3 (Munger et al., [@B73]; Annes et al., [@B4]; Mu et al., [@B71]; Araya et al., [@B6]).

The integrin identified as a TGF-β activator *in vivo* is α~v~β~6~, which can directly activate latent TGF-β1 independently from any proteolytic activity (Munger et al., [@B73]). The α~v~β~6~ integrin-mediated activation of latent TGF-β depends on a direct interaction between integrin α~v~β~6~ and the RGD amino acid sequence present in LAP β1 and LAP β3. However, binding alone is not sufficient to activate the latent complex (Munger et al., [@B73]). The interaction of the β~6~ cytoplasmic domain with the actin cytoskeleton is mandatory for this activation (Munger et al., [@B73]). LTBP-1 is identified as being a major regulatory factor in α~v~β~6~-integrin-mediated TGF-β activation. This activation requires a covalent interaction between LAP and the third cysteine-rich domain in LTBP mediated by a hinge domain of LTBP-1 (Annes et al., [@B2]). Since the hinge domain of LTBP-1 is not conserved among other LTBP isoforms, α~v~β~6~-mediated TGF-β activation via LTBP-1 is isoform specific (Annes et al., [@B2]; Wipff and Hinz, [@B121]). In response to tissue injury or tissue damage, integrin α~v~β~6~ induces a conformational change of latent TGF-β via the interactions between integrin α~v~β~6~ and actin cytoskeleton (Munger et al., [@B73]; Wipff and Hinz, [@B121]; Shi et al., [@B98]). Such a conformational change makes it possible to cause mature TGF-β to interact with the TGF-β type II receptor (Munger et al., [@B73]; Wipff and Hinz, [@B121]; Shi et al., [@B98]). There is no release of LAP or active TGF-β1 once latent TGF-β associates with integrin α~v~β~6~. Although a profibrogenic drug bleomycin induces lung fibrosis in wild-type mice by up-regulation of integrin β6 expression in alveolar epithelial cells and activation of TGF-β, even high dose of bleomycin administration cannot cause fibrosis in integrin β6-null mice (Munger et al., [@B73]).

TSP-1-medaited TGF-β activation
-------------------------------

The matricellular protein TSP-1 was first shown as a component of the α-granule in platelets and can act as a major activator of latent TGF-β1 (Mosher, [@B69]; Crawford et al., [@B19]). TSP-1 is prominently expressed in response to tissue damage or stress and plays a role as a transient component of ECM during tissue repair (Mosher, [@B69]; Adams, [@B1]; Kyriakides and Maclauchlan, [@B54]). TSP-1 binds to matrix components, proteases, cytokines, and growth factors and activates intracellular signals via its multiple domains, and thereby modulates cell adhesion, inhibition of angiogenesis, and reconstruction of the ECM (Bornstein, [@B12]). Furthermore, TSP-1 can activate latent TGF-β1 *in vitro* (Schultz-Cherry and Murphy-Ullrich, [@B94]; Schultz-Cherry et al., [@B95]) and *in vivo* (Crawford et al., [@B19]). Indeed, TSP-1 activates recombinant small and large latent TGF-βs even in a cell-free system, and this activation is inhibited by a specific antibody for the amino-terminus of the LAP but not for the COOH terminus of the LAP and the LTBP (Schultz-Cherry et al., [@B95]). Thus, TSP-1 binds small latent TGF-β and large latent TGF-β, and this binding interaction is sufficient to generate biologically active TGF-β. The two sequences (GGWSHW and KRFK) located in the type I repeat of TSP-1 comprise the region responsible for binding and activating latent TGF-β, respectively (Goundis and Reid, [@B34]; Schultz-Cherry et al., [@B96]). In LAP, a sequence LSKL near the amino-terminus plays a pivotal role in the interaction and TSP-1-mediated activation of latent TGF-β, because LSKL peptides competitively inhibit TSP-1- or a KRFK-peptide-mediated latent TGF-β activation (Ribeiro et al., [@B86]). Furthermore, mutations of the LSKL sequence in LAP reduce the binding of LAP to the mature TGF-β and induce the impaired ability of LAP to confer latency to mature TGF-β (Young and Murphy-Ullrich, [@B125]). Such a direct interaction between TSP-1 and LAP is supposed to induce a conformational change of LAP in relation to mature TGF-β and thereby presumably unmask the TGF-β receptor binding site that can bind to its receptor (Murphy-Ullrich and Poczatek, [@B74]). To further understand TSP-1-mediated TGF-β activation, the nature of structural restraints imposed on LAP in the presence of bound TSP-1 would be useful. TSP-1-null mice have an inflammatory phenotype similar to that of TGF-β1-null mice in several organs, including pancreas and lung, whereas the inflammatory changes observed in TSP-1-null mice are not as severe as those in TGF-β1-null mice (Crawford et al., [@B19]). Treatment of TSP-1-null mice with the TSP-1 derived peptide KRFK, which activates TGF-β1, rescues the abnormal phenotypes in pancreas and lung (Crawford et al., [@B19]). In contrast, the treatment of wild-type mice with the peptide LSKL, which blocks TGF-β activation, results in the abnormalities in pancreas and lung, and these phenotypes are very similar to those of TSP-1-null mice and TGF-β1-null mice (Crawford et al., [@B19]).

Protease-mediated TGF-β activation
----------------------------------

A number of proteases, including plasmin, matrix metalloproteinase (MMP)-2/9, and a disintegrin and metalloproteinase with TSP motifs 1 (ADAMTS1), have been identified as latent TGF-β activators *in vitro* (Lyons et al., [@B58]; Sato and Rifkin, [@B91]; Yu and Stamenkovic, [@B126]; Bourd-Boittin et al., [@B14]). Plasmin and MMP-2/9 belong to the serine protease and metalloproteinase families, respectively. The proteinase-sensitive hinge region in LTBP is suggested to be a potential target for the release of a still-latent remnant of the large latent complex (Taipale et al., [@B106]). Using a co-culture system of endothelial cells and pericytes or smooth muscle cells, plasmin has been identified as one of the latent TGF-β activators *in vitro*: the active TGF-β formation is blocked by plasmin inhibitors (Sato and Rifkin, [@B91]) or prolonged by neutralizing antibody to plasminogen activator inhibitor-1 (Sato et al., [@B92]). The treatments of fibroblast- or Chinese hamster ovary cell-conditional medium with plasmin can generate the active form of TGF-β (Lyons et al., [@B58], [@B57]). Thus, the proteinase-mediated TGF-β activation system appears to be important in activation of latent TGF-β in several models *in vitro*. However, there is still no definite evidence of proteinase-dependent TGF-β activation *in vivo*. Indeed, plasminogen (plasmin pro-enzyme)-null mice show normal embryonic development, survive to adulthood, are fertile, and display none of the pathological features shown in TGF-β-null mice (Bugge et al., [@B15]).

TGF-β Activation Mechanism and Availability of Latent TGF-β Complex in Liver Diseases
=====================================================================================

Transforming growth factor-β signal induces the transition of quiescent hepatic stellate cells (HSCs) into contractile fibrogenic myofibroblasts, which is the key event in the pathobiology of liver fibrosis (Bissell et al., [@B9]; Dooley et al., [@B25]; Gressner and Weiskirchen, [@B37]). Myofibroblasts play a central role in the production of ECM components such as fibronectin, collagen type I and III. Continuous and/or upregulated TGF-β-signaling, such as in chronic liver injury, induces sustained activation of myofibroblasts and results in liver fibrosis (Bissell et al., [@B9]; Tahashi et al., [@B105]; Gressner and Weiskirchen, [@B37]). Active TGF-β-signaling acts on hepatocytes as an anti-proliferative factor in culture, and administration of TGF-β inhibits the hepatocyte proliferation during liver regeneration after partial hepatectomy (Russell et al., [@B87]). Genetic ablation of TGF-β-signals using TGF type II receptor-knockout mice actually accelerates hepatocyte proliferation after partial hepatectomy (Oe et al., [@B78]). Thus, locally activated TGF-β-signaling is involved in the repair following liver injury, and the therapeutic strategies targeting local TGF-β activation in fibrogenesis are now under intense investigation (Table [2](#T2){ref-type="table"}).

###### 

**Therapeutic target for TGF-β activation mechanism *in vivo***.

  Target model                      Reagent      Effect     TGF-β activity   Reference
  --------------------------------- ------------ ---------- ---------------- --------------------------------------------
  **INTEGRIN β6**                                                            
  BDL-induced liver fibrosis        Antagonist   Decrease   Decrease         Patsenker et al. ([@B81])
  BDL-induced liver fibrosis        Antibody     Decrease   NA               Wang et al. ([@B119])
  Bleomycin-induced lung fibrosis   Antibody     Decrease   Decrease         Horan et al. ([@B40])
  Radiation-induced lung fibrosis   Antibody     Decrease   NA               Puthawala et al. ([@B85])
  **TSP-1**                                                                  
  Bleomycin-induced lung fibrosis   Peptide      Decrease   Decrease         Chen et al. ([@B17]), Chen et al. ([@B18])
  UUO-induced renal fibrosis        Peptide      Decrease   Decrease         Xie et al. ([@B122])
  DMN-induced liver fibrosis        Peptide      Decrease   Decrease         Kondou et al. ([@B52])
  **PLASMIN**                                                                
  PC-induced liver fibrosis         Inhibitor    Decrease   Decrease         Okuno et al. ([@B79])
  **ADAMTS1**                                                                
  CCl~4~-induced liver fibrosis     Peptide      Decrease   NA               Bourd-Boittin et al. ([@B14])

*TGF-β, transforming growth factor-β; PC, porcine serum; BDL, bile duct ligation; NA, not available; TSP-1, thrombospondin-1; UUO, Unilateral ureteral obstruction; DMN, dimethylnitrosamine; CCl~4~, carbon tetrachloride*.

β6 integrin-mediated local TGF-β bioavailability and liver diseases
-------------------------------------------------------------------

Expression of α~v~β~6~-integrin is virtually absent except in cholangiocytes in normal liver, but its expression in cholangiocytes is highly upregulated in thioacetamide- and bile duct ligation-induced fibrotic liver (Wang et al., [@B119]; Popov et al., [@B82]). Deficiency in integrin β~6~ attenuates liver fibrosis after bile duct ligation, which is accompanied by a decrease in active TGF-β-signaling (Wang et al., [@B119]). In human fibrogenic liver diseases (e.g., primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease, and hepatitis B or C), α*~v~*β*~6~-integrin* mRNA levels are upregulated compared to levels in healthy livers (Popov et al., [@B82]). Furthermore, α*~v~*β*~6~-integrin* mRNA levels correlate with the progression of fibrosis in patients with chronic hepatitis C (Popov et al., [@B82]). These findings suggest that α~v~β~6~-integrin may be involved not only in classic biliary type fibrosis but also in a variety of liver fibrogenic diseases with different etiologies (Popov et al., [@B82]).

TSP-1-medaited local TGF-β bioavailability and liver diseases
-------------------------------------------------------------

The roles of TSP-1/TGF-β1 interdependence during liver regeneration remain to be elucidated. We have investigated whether TSP-1 is a suitable molecular target for accelerating liver regeneration after partial hepatectomy using a TSP-1-deficient mouse model. We have found that TSP-1 is prominently induced in endothelial cells of wild-type livers in response to partial hepatectomy, and thereafter TGF-β signal is activated. TSP-1 deficiency results in significantly reduced TGF-β/Smad signaling and accelerated hepatocyte proliferation via downregulation of p21 protein expression. TSP-1 expression in endothelial cells such as human umbilical vein endothelial cells (HUVECs) is induced by reactive oxygen species (ROS) in culture. Treatment of those conditioned media from HUVECs with primary hepatocytes actually induces phosphorylation of Smad2. Furthermore, pretreatment of primary hepatocytes with the TSP-1-inhibitory peptide LSKL significantly suppresses conditioned media-induced phosphorylation of Smad2, whereas pretreatment of primary hepatocytes with the control peptide SLLK shows no effects. Thus, these findings indicate that TSP-1 plays a negative role in liver regeneration through local TGF-β1 activation (Hayashi et al., [@B39]). Furthermore, treatment with the TSP-1 inhibitory peptide LSKL reduces local TGF-β activity and suppresses the progression of liver fibrosis in a dimethylnitrosamine (DMN)-treated rat liver fibrosis model, suggesting that TSP-1-mediated local TGF-β activation is associated with liver fibrogenesis (Kondou et al., [@B52]).

Fibronectin-mediated local TGF-β bioavailability and liver diseases
-------------------------------------------------------------------

Fibronectin is a major ECM component and exists in soluble (plasma fibronectin) and insoluble form (cellular fibronectin) as a part of the ECM (Hynes, [@B41]; Mosher, [@B68]). Fibronectin participates in the incorporation of LTBP-1 into the ECM *in vitro* (Dallas et al., [@B22]). Fibronectin-null cells show poor activity vis-à-vis LTBP-1 incorporation into the ECM and exhibit deficient activation of latent TGF-β1 even after transfection by the integrin α~v~β~6~, suggesting that fibronectin is necessary to the ECM scaffold for LTBP-1 deposition (Fontana et al., [@B30]). To investigate the interdependence of fibronectin and TGF-β on the fibrogenic response to adult tissue damage, we recently established a null condition for both fibronectin isoforms (plasma and cellular types) from adult mouse liver. Since it has been proposed that collagen organization and assembly depend on the fibronectin matrix in culture (Sottile and Hocking, [@B102]; Velling et al., [@B116]; Sottile et al., [@B103]), we have explored whether fibronectin would be a suitable molecular target for preventing the extensive collagen deposits and scar formation that could lead to liver fibrosis. We have demonstrated that the lack of fibronectin does not actually interfere with reconstruction of collagen fibril organization in response to carbon tetrachloride-induced liver injury. Fibronectin deficiency results in elevated local TGF-β bioavailability post injury, and it is mediated largely by β6 integrin. Furthermore, we have identified TGF-β-signaling and type V collagen as essential elements for collagen fibrillogenesis in adult tissue remodeling (Moriya et al., [@B67]). Our findings imply that fibronectin regulates the balance of active and inactive (latent) TGF-β, which in turn modulates ECM production and remodeling and consequently maintains adult liver homeostasis. Indeed, mouse models of TGF-β1 overexpression show dominant phenotypes such as advanced liver fibrosis (Sanderson et al., [@B89]; Ueberham et al., [@B112]). These observations support the hypothesis that LTBP and its binding molecules such as fibronectin determine the spatial localization of LTBP in tissues, thereby regulating the extent of local TGF-β bioavailability. Since locally activated TGF-β induces the production of type V collagen in response to liver damage, it remains to be elucidated whether type V collagen-nucleated collagen fibrillogenesis contributes to adult chronic fibrotic diseases.

Proteinase-mediated local TGF-β bioavailability and liver diseases
------------------------------------------------------------------

A very recent study using a proteinase-related gene sample identified ADAMTS1 as an upregulated fibrosis-related protease in human liver fibrosis (Bourd-Boittin et al., [@B14]). ADAMTSs are characterized by an ancillary domain containing one or more TSP type 1 repeats (Apte, [@B5]). ADAMTSs are secreted as cell surface proteins and associate with ECM components. ADAMTS1 is synthesized as a 110-kDa latent form and processed by HSCs as 87-kDa mature forms in fibrotic tissues (Bourd-Boittin et al., [@B14]). A major feature of ADAMTS1 is the presence of three TSP type 1 motifs and a KTFR motif. There is a direct interaction between ADAMTS1 and LAP, and ADAMTS1 induces local TGF-β activation through the interaction between ADAMTS1-derived KTFR and LAP-derived LSKL (Bourd-Boittin et al., [@B14]). The expression of ADAMTS1 is induced in mouse chronic liver fibrosis model induced by carbon tetrachloride, and administrations of KTFR peptide reduce liver fibrosis (Bourd-Boittin et al., [@B14]). Another study demonstrated that plasmin inhibitor, camostat mesilate, can suppress TGF-β activation in HSCs *in vitro*, and oral administrations of camostat mesilate attenuates the development of porcine-serum-induced liver fibrosis in rats (Okuno et al., [@B79]).

Transglutaminase-mediated local TGF-β bioavailability and liver diseases
------------------------------------------------------------------------

Covalent cross-linking between proteins is catalyzed by transglutaminases. This is an important process for tissue remodeling, as it generates extra rigidity and a resistance against proteolytic degradation. The family of transglutaminases (EC2.3.2.13) consists of eight family members (transglutaminase 1--7 and plasma coagulation factor XIII (Beninati and Piacentini, [@B7]). The covalent association between LTBP-1 and the ECM depends on transglutaminase-mediated cross-linking, because little LTBP-1 is recovered from matrix digests prepared from cultures treated with transglutaminase inhibitors (Nunes et al., [@B77]). Furthermore, transglutaminase inhibitors prevent TGF-β1 activation in a co-culture of bovine aortic endothelial cells and bovine smooth muscle cells (Kojima et al., [@B49]). Thus, transglutaminase is important for the LTBP anchoring to ECM, and transglutaminase inhibitors affect TGF-β1 activity *in vitro*. Transglutaminase 2 is involved in several human diseases, in wound healing and fibrosis, and represents promising pharmacological targets (Verderio et al., [@B117]; Caccamo et al., [@B16]). Indeed, transglutaminase 2 deficiency reduces levels of active TGF-β1 and attenuates the interstitial renal fibrosis induced by unilateral ureteral obstruction in mice (Shweke et al., [@B100]).

Elevated transglutaminase 2 expression and activity are observed in human fibrotic (Grenard et al., [@B36]) and mouse CCl~4~-treated livers (Nardacci et al., [@B75]; Popov et al., [@B83]). Transglutaminase 2-null mice fail to clear hepatic necrotic tissues and to rearrange the hepatic lobular architecture with a progressive accumulation of ECM components and inflammatory cells in CCl~4~-induced chronic liver injury, indicating that transglutaminase 2 plays a protective role in tissue stability and repair after liver injury (Nardacci et al., [@B75]; Popov et al., [@B83]). Very recently, Popov et al. ([@B83]) assessed whether transglutaminase 2 was implicated in irreversible collagen stabilization in liver fibrosis. Transglutaminase 2 activity is upregulated during hepatic fibrogenesis or stabilization of collagen matrix. However, unexpectedly, transglutaminase 2 deficiency does not promote regression of liver fibrosis (Popov et al., [@B83]). Thus, there exists transglutaminase 2-independent irreversible collagen cross-linking in the progression of liver fibrosis (Popov et al., [@B83]).

Although most antifibrotic strategies are directed against HSC/myofibroblast proliferation and profibrogenic activation, few studies have targeted ECM stabilization. Considering the evidence that the instability of ECM bounded latent TGF-β complex results in altered TGF-β availability (Maeda et al., [@B59]), the targeting for ECM-mediated TGF-β bioavailability would be an alternative therapeutic approach for preventing progression of liver fibrosis.

Perspective
===========

Transforming growth factor-β is synthesized as a small latent complex (mature TGF-β and LAP) and thereafter covalently interacts with LTBPs as the large latent complex. The large latent complex is associated with ECM components, fibrillin, and fibronectin. Such a well and tightly orchestrated regulation in latency of TGF-β enables an immediate and highly localized response to type-specific tissue injury without *de novo* synthesis.

Both β6 integrin- and TSP-1-mediated local TGF-β activation are involved in the pathogenesis of liver diseases. Interestingly, in other organs such as lung, the lack of TSP-1 does not affect TGF-β bioavailability and does not protect from bleomycin-induced pulmonary fibrosis (Ezzie et al., [@B28]). In the thrombopoietin-induced bone marrow myelofibrosis model, TSP-1 deficiency does not attenuate local TGF-β bioavailability and myelofibrosis (Evrard et al., [@B27]). Thus, mechanisms of local TGF-β activation and their biological significance in the pathological process are likely to be tissue specific.

Based on the TGF-β signaling pathway, four major strategies allowing the modulation of TGF-β availability have emerged. The first strategy is to block the production of TGF-β using anti-sense oligonucleotide mRNA; a second is to use monoclonal antibodies to block specific TGF-β isoforms; a third is to use the intracellular signal inhibitors that block the TGF-β receptor activation and downstream signaling; and a fourth, which constitutes the main focus of this review, is to block the local activation of latent TGF-β. Since TGF-β has so many important physiological functions, as evidenced by TGF-β-null mice, a long-term global inhibition of TGF-β activity might potentially lead to undesirable side effects, such as aberrant immune activation, impaired wound healing, and malignant cell transformation (Kulkarni et al., [@B53]; Mallat et al., [@B60]; Bhowmick et al., [@B8]). Careful targeting of the TGF-β pathway to minimize systemic effects is clearly a highly desirable goal. Anti-TGF-β strategies to selectively block latent TGF-β activation at local sites where excess TGF-β activation occurs are attractive and logical. The benefits of therapeutic strategies targeting local TGF-β activation are under intense investigation. Future studies will yield valuable data about these strategies for liver diseases.
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